Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1975782 | 0.82 | SMN1; SMN2 (0.44) | POLBTDP1NAMPTLMNAALDH1A1 | |
| SCHEMBL1974456 | 0.78 | POLB (0.46) | POLBNAMPTLMNAALDH1A1TSHR | |
| SCHEMBL1976236 | 0.76 | ALDH1A1 (0.56) | POLBLMNAALDH1A1TSHRKMT2A | |
| SCHEMBL1975415 | 0.75 | TSHR (0.35) | LMNAALDH1A1TSHRL3MBTL1SMN1; SMN2 | |
| SCHEMBL12509539 | 0.70 | NAMPT (0.53) | POLBTDP1NAMPTLMNAALDH1A1 | |
| SCHEMBL24598776 | 0.67 | PREP (0.41) | MAPT | |
| SCHEMBL12422709 | 0.67 | POLB (0.68) | POLBTDP1LMNAALDH1A1TSHR | |
| SCHEMBL8670594 | 0.67 | NPY5R (0.41) | POLBTDP1LMNAALDH1A1TSHR | |
| SCHEMBL1575569 | 0.65 | NPY5R (0.40) | TSHR | |
| SCHEMBL12169346 | 0.65 | L3MBTL1 (0.64) | POLBLMNAALDH1A1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658129-B2 | Agents and methods for the imaging of myelin basic protein | GENERAL ELECTRIC COMPANY (US) | 2014-02-25 | — | — | US | disclosed |
| US-20110142759-A1 | AGENTS AND METHODS FOR THE IMAGING OF MYELIN BASIC PROTEIN | GENERAL ELECTRIC COMPANY (US) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110142759-A1 | AGENTS AND METHODS FOR THE IMAGING OF MYELIN BASIC PROTEIN | MAG, PMP22, MYT1 | POLB 2829/4885TDP1 2426/4885NAMPT 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.